Innovative Clinical Trials: The LUNG-MAP Study
| Autor: | Vassiliki A. Papadimitrakopoulou, David R. Gandara, M. W. Redman, Philip C. Mack, Suresh S. Ramalingam, R. S. Herbst, Fred R. Hirsch, Conor E. Steuer |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Oncology
medicine.medical_specialty Lung Neoplasms medicine.medical_treatment Antineoplastic Agents Disease Targeted therapy Clinical Trials Phase II as Topic Carcinoma Non-Small-Cell Lung Internal medicine Biomarkers Tumor Carcinoma Humans Medicine Genetic Predisposition to Disease Pharmacology (medical) Molecular Targeted Therapy Precision Medicine Pharmacology Squamous-cell carcinoma of the lung business.industry Genomics Precision medicine medicine.disease Surgery Clinical trial Phenotype Clinical Trials Phase III as Topic Drug development Research Design Carcinoma Squamous Cell Adenocarcinoma business Signal Transduction |
| Zdroj: | Clinical Pharmacology & Therapeutics. 97:488-491 |
| ISSN: | 0009-9236 |
| DOI: | 10.1002/cpt.88 |
| Popis: | Although the proportion of patients with squamous cell carcinoma of the lung has declined over the last two decades, the disease is still fatal for tens of thousands of patients each year. The treatment of non-small cell lung cancer has advanced rapidly over the past decade, providing novel, targeted therapeutic options to patients, but has mostly been limited to the adenocarcinoma histology. Efforts are currently underway to bring squamous cell carcinoma of the lung into this new era of targeted therapy. This article reviews the rationale and trial design for the "LUNG-MAP: S1400 Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer" study. This multi-institutional, multi-cooperative group trial aims to individualize treatment for patients with metastatic squamous cell carcinoma to one of five arms based on the genomic profile of the tumor. The goal of this clinical trial is to rapidly identify new active drugs and bring them as soon as possible through a registration process for patients with squamous cell lung cancer by utilizing a novel trial design and involving all key stakeholders in drug development in a national effort. This could serve as a paradigm for drug development for malignancies with wide molecular heterogeneity. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text